Low-dose minocycline hydrochloride is better than doxycycline for treating moderate to severe rosacea, according to two new phase 3 trials.
Amid concerns about antibiotic resistance, these findings support the idea that lower doses can be effective, while also being better, safer, simpler easier and cheaper, said West Australian dermatologist Clinical Associate Professor Kurt Gebauer OAM, who was not involved in the studies.
The double-blind randomised controlled trials found that the formulation, known as DFD-29, was more successful and reduced inflammatory lesions compared to both doxycycline and placebo. It includes 10mg immediate-release and 30mg extended-release minocycline.
“The results of these placebo-controlled randomised clinical trials demonstrate that DFD-29 is efficacious and provides significantly superior outcomes in rosacea compared with placebo and doxycycline with comparable adverse events,” the authors wrote in JAMA Dermatology .
“These results indicate that DFD-29, 40mg, may be an appropriate treatment option for the systemic treatment of rosacea.”
